Equities Analysts Offer Predictions for Veru Q4 Earnings

Veru Inc. (NASDAQ:VERU) – B. Riley decreased their Q4 2025 earnings per share (EPS) estimates for shares of Veru in a research note issued to investors on Wednesday, May 14th. B. Riley analyst W. Wood now forecasts that the company will earn ($0.06) per share for the quarter, down from their prior forecast of ($0.05). The consensus estimate for Veru’s current full-year earnings is ($0.22) per share. B. Riley also issued estimates for Veru’s FY2026 earnings at ($0.24) EPS.

Veru Price Performance

VERU stock opened at $0.51 on Monday. The company has a fifty day moving average price of $0.53 and a 200 day moving average price of $0.62. Veru has a 12 month low of $0.45 and a 12 month high of $1.50. The company has a market cap of $74.74 million, a price-to-earnings ratio of -1.96 and a beta of -0.74.

Veru (NASDAQ:VERU) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. MPM Bioimpact LLC boosted its stake in shares of Veru by 53.8% during the first quarter. MPM Bioimpact LLC now owns 6,592,727 shares of the company’s stock worth $3,231,000 after buying an additional 2,307,362 shares during the period. Geode Capital Management LLC raised its stake in Veru by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 2,997,751 shares of the company’s stock valued at $1,950,000 after acquiring an additional 57,611 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in Veru by 17.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 1,423,288 shares of the company’s stock worth $698,000 after acquiring an additional 206,614 shares during the period. Oppenheimer & Co. Inc. grew its stake in shares of Veru by 18.3% in the 1st quarter. Oppenheimer & Co. Inc. now owns 1,325,246 shares of the company’s stock valued at $650,000 after purchasing an additional 204,660 shares during the last quarter. Finally, PVG Asset Management Corp grew its stake in shares of Veru by 64.4% in the 4th quarter. PVG Asset Management Corp now owns 1,047,310 shares of the company’s stock valued at $681,000 after purchasing an additional 410,340 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.